A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter’s Transformation

Table 2

Treatment summary.

	Patient 1	Patient 2	Patient 3	Patient 4
# of cycles of A + AVD	6	6	6	6
Dose reduction	Brentuximab dose reduced starting cycle 6 for neuropathy	Brentuximab dose reduced starting cycle 4 for neuropathy	No	No
Interim PET response	CR, Deauville 2	PR, Deauville 4	CR, Deauville 3	PR, Deauville 4
End of treatment response	CR	CR	PD, Deauville 5	PD, Deauville 5
Subsequent HvRT therapy	No	No	(1) GDP	(1) R-ICE
			(2) Nivolumab	(2) Allogeneic stem cell transplant
			(3) Bendamustine + brentuximab
Residual CLL after completion of treatment	No	Yes	Yes	Yes
Additional CLL directed therapy	No	Acalabrutinib	(1) Rituximab	No
			(2) R-CVP

A + AVD = brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine; PET = positron emission Ttomography; HvRT = Hodgkin lymphoma variant of Richter’s transformation; CLL = chronic lymphocytic leukemia; CR = complete response; PR = partial response; PD = disease progression; GDP = gemcitabine, dexamethasone, and cisplatin; R-CVP = rituximab, cyclophosphamide, vincristine, and prednisone; R-ICE = rituximab, ifosfamide, carboplatin, and etoposide.